ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1¡¢12ÔÂ4ºÅ£¬£¬£¬£¬£¬£¬°ÙÃ÷ÐÅ¿µÐû²¼£¬£¬£¬£¬£¬£¬¹«Ë¾ÍêȫӵÓÐ×ÔÖ÷֪ʶ²úȨµÄÕë¶Ô¸ñÀ×·ò˹֢ÖÎÁƵÄÁ¢ÒìÐÔÁÆ·¨£¨WP1302£©»ñFDA¶þÆÚÁÙ´²ÔÊÐí£¬£¬£¬£¬£¬£¬ÕâÊǸü²²¡ÖÎÁÆÁìÓòµÄÒ»¸öÖØ´óÍ»ÆÆ¡£¡£¡£¡£¸ñÀ×·ò˹֢£¬£¬£¬£¬£¬£¬×÷Ϊ×î³£¼ûµÄ×ÔÉíÃâÒßÐÔ¼²²¡Ö®Ò»£¬£¬£¬£¬£¬£¬ÔÚÈ«Çòî¾Êܸü²²¡À§ÈŵϼÕßÖڶ࣬£¬£¬£¬£¬£¬½öÎ÷Å·¾ÍÔ¼´ï1000Íò¡£¡£¡£¡£ÕâÖÖ¼²²¡Ö÷ÒªÌåÏÖΪÃâÒßϵͳ¹ýʧµØ¹¥»÷¼××´ÏÙ£¬£¬£¬£¬£¬£¬µ¼Ö¼××´ÏÙ¼¤ËعýÁ¿ÉøÍ¸£¬£¬£¬£¬£¬£¬´Ó¶øÒý·¢ÌåÖØ¼õÇᡢͻÑ۵ȼ××´ÏÙ¿º½øÖ¢×´¡£¡£¡£¡£WP1302×÷Ϊ¸ñÀ×·ò˹֢ÖÎÁÆÁìÓò70ÄêÀ´Ê׸öÒ²ÊÇΨÖðÒ»¸öÁ¢ÒìÁÆ·¨£¬£¬£¬£¬£¬£¬ÆäÔÚÅ·ÖÞÍê³ÉµÄ1ÆÚÁÙ´²ÊÔÑéЧ¹ûÒѾÆðÔ´ÏÔʾ³ö¶Ô´ó´ó¶¼»¼ÕßµÄÏÔÖøÖÎÁÆÐ§¹û£¬£¬£¬£¬£¬£¬²¢¾ßÓÐÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£
2¡¢12ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬¿Æ¼ÃÒ©ÒµÐû²¼£¬£¬£¬£¬£¬£¬ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒÑÅú×¼CT071µÄINDÉêÇ룬£¬£¬£¬£¬£¬Ò»ÖÖ°ÐÏòGÂѰ׿ÁªÊÜÌåC×é5³ÉÔ±D£¨GPRC5D£©µÄ×ÔÌåCAR-Tϸ°ûºòÑ¡²úÆ·£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƸ´·¢/ÄÑÖζ෢ÐÔ¹ÇËèÁö£¨MM£©»ò¸´·¢/ÄÑÖÎÔ·¢ÐÔ½¬Ï¸°û°×Ѫ²¡£¡£¡£¡£¨PCL£©µÄ»¼Õß¡£¡£¡£¡£
3¡¢12ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬Ê¿ÔóÉúÎïÒ½Ò©£¨ËÕÖÝ£©ÓÐÏÞ¹«Ë¾ÓÚ2023Äê11ÔÂÈ«ÇòÊ×·¢Ñз¢¹ÜÏßÁÙ´²¼¶iPSCÑÜÉúÑÇÐÍÉñ¾Ç°Ìåϸ°û²úÆ·ÖÎÁƽ¥¶³Ö¢£¨¼¡Î®Ëõ²àË÷Ó²»¯Ö¢£¬£¬£¬£¬£¬£¬ALS£©»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©ÈÏÖ¤ÊÚÓè¹Â¶ùÒ©×ʸñ£¬£¬£¬£¬£¬£¬³ÉΪÊׯäÖйú×ÔÑк͹ú²úiPSÑÜÉúϸ°ûÒ©»ñµÃFDAÈÏÖ¤²¢ÊÚÓè¹Â¶ùÒ©×ʸñ¡¢Ò²ÊÇÆù½ñΪֹȫÇòÊ׸öÓÃÓÚÖÎÁƽ¥¶³Ö¢µÄÓµÓй¶ùÒ©×ʸñµÄiPSÑÜÉúϸ°ûÒ©Îï¡£¡£¡£¡£
4¡¢12ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬Ôƶ¥ÐÂÒ«Ðû²¼Öйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©ÒÑÊÜÀízetomipzomib£¨ÔóÍÐ×ôÃ×£©ÔÚÖйúµÄÐÂÒ©ÁÙ´²ÊÔÑ飨IND£©ÉêÇë¡£¡£¡£¡£ZetomipzomibÊÇÒ»¿îÐÂÒ»ÀàÊ×´´¡¢Ñ¡ÔñÐÔÃâÒßÂѰ×øÌåÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁưüÀ¨ÀÇ´¯ÐÔÉöÑס¢ÏµÍ³ÐÔºì°ßÀÇ´¯ÔÚÄÚµÄһϵÁÐ×ÔÉíÃâÒßÐÔ¼²²¡¡£¡£¡£¡£
1¡¢12ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬ÂÞÊÏÐû¹«¸æ¿¢×îÖպϲ¢ÐÒ飬£¬£¬£¬£¬£¬ÊÕ¹ºÃÀ¹ú˽Ӫ¹«Ë¾Carmot Therapeutics, Inc.¡£¡£¡£¡£´Ë´ÎÊÕ¹ºÊ¹ÂÞÊÏ»ñµÃÁ˲î±ð»¯µÄÒȵºËزúÆ·×éºÏ£¬£¬£¬£¬£¬£¬°üÀ¨£ºCT-388¡¢CT-996¼°CT-868¡£¡£¡£¡£Æ¾Ö¤ÐÒéÌõ¿î£¬£¬£¬£¬£¬£¬ÂÞÊϽ«ÔÚÉúÒâÍê³ÉʱÏòCarmot¹É¶«Ö§¸¶ÏÖ½ðÊÕ¹º¼Û27ÒÚÃÀÔª¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬Carmot¹ÉȨ³ÖÓÐÈËÓÐȨƾ֤ijЩÀï³Ì±®µÄʵÏÖ»ñµÃ¸ß´ï4ÒÚÃÀÔª¸¶¿î¡£¡£¡£¡£ÉúÒâÍê³Éºó£¬£¬£¬£¬£¬£¬ÂÞÊϽ«»ñµÃCarmotÏÖÔÚµÄÑз¢×éºÏ£¬£¬£¬£¬£¬£¬°üÀ¨ËùÓÐÁÙ´²ºÍÁÙ´²Ç°×ʲú£¬£¬£¬£¬£¬£¬Carmot¼°ÆäÔ±¹¤½«¼ÓÈëÂÞÊϼ¯ÍÅ£¬£¬£¬£¬£¬£¬³ÉΪÂÞÊÏÖÆÒ©²¿·ÖµÄÒ»²¿·Ö¡£¡£¡£¡£ÂÞÊÏ»¹½«¶À¼ÒʹÓÃCarmotÔÚ´úлÁìÓòµÄÁ¢ÒìChemotype Evolution·¢Ã÷ƽ̨£¬£¬£¬£¬£¬£¬ÒÔ½øÒ»²½ÔöÇ¿ÂÞÊÏÔÚÐÄѪ¹ÜºÍ´úл¼²²¡ÁìÓòµÄÑз¢ÊÂÇéºÍ²úÆ·×éºÏ¡£¡£¡£¡£ÏÖÔÚÔ¤¼ÆÉúÒ⽫ÓÚ2024ÄêµÚÒ»¼¾¶ÈÍê³É¡£¡£¡£¡£
1¡¢¿ËÈÕ£¬£¬£¬£¬£¬£¬ÖйúÒ½¿Æ´óѧÎâç÷¿¡¼°¹þ¶û±õÒ½¿Æ´óѧÄþÉÐΰ¿ÆÑÐÍŶӶÔ80¸öCCC¡¢79¸öEC¡¢80¸öSCºÍ30¸ö±ÈÕÕÑùÆ·¾ÙÐÐÖÜÈ«µÄÂѰ×ÖÊ×éѧÆÊÎö¡£¡£¡£¡£Ñо¿ÆÊÎöÕ¹ÏÖÁËÖ÷Ҫͨ·ÖÐʧµ÷ÂѰ׺ÍÁ×ËữλµãµÄÔ¤ºó»òÕï¶Ï¼ÛÖµ¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬ÂѰ×Öʹ²±í´ïÍøÂç²»µ«ÌṩÁËÿÖÖ×é֯ѧÑÇÐ͵ÄÉúÎïÑ§ÌØÕ÷µÄÖÜÈ«ÊÓͼ£¬£¬£¬£¬£¬£¬²¢ÇÒ»¹Ö¸Ê¾ÁËDZÔÚµÄÔ¤ºóÉúÎï±ê¼ÇÎïºÍÏ£Íû±ê¼Ç¡£¡£¡£¡£ÖµµÃ×¢ÖØµÄÊÇ£¬£¬£¬£¬£¬£¬EOC¾ßÓкÜÇ¿µÄÖ×Áö¼äÒìÖÊÐÔ£¬£¬£¬£¬£¬£¬ÔÚCCC¡¢ECºÍSCÖоßÓÐÏÔÖø²î±ðµÄÁÙ´²ÌØÕ÷¡¢ÂѰ×ÖÊ×éѧģʽºÍÐźÅͨ·Õϰ¡£¡£¡£¡£×îºó£¬£¬£¬£¬£¬£¬Ñо¿ÍƶÏMPP7ÂѰ×ÊÇSCµÄDZÔÚÖÎÁưе㣬£¬£¬£¬£¬£¬ÆäÉúÎïѧ¹¦Ð§ÔÚSCϸ°ûÖлñµÃ֤ʵ¡£¡£¡£¡£±¾ÏîÑо¿½ÒÏþÔÚNature CommunicationsÉÏ[1]¡£¡£¡£¡£
[1] Gong, TT., Guo, S., Liu, FH. et al. Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes. Nat Commun 14, 7802 (2023).
Ïà¹ØÐÂÎÅ